Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 clinical trial of VY-AADC for Parkinson's disease

Trial Profile

A phase 3 clinical trial of VY-AADC for Parkinson's disease

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezaladcigene resoparvovec (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms RESTORE-2
  • Sponsors Voyager Therapeutics

Most Recent Events

  • 11 Sep 2020 According to a Neurocrine Biosciences media release, preparations are ongoing for this global registrational trial that will include clinical sites within and outside the U.S.
  • 10 Aug 2020 event According to a Neurocrine Biosciences media release , it plan to initiate the RESTORE-2 Phase 3 global registrational clinical study of VY-AADC (NBIb-1817) in Parkinsons disease during the first half of 2021.
  • 12 Jan 2020 According to a Neurocrine Biosciences media release, the company expects to initiate this trial in 2H 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top